COCP News and Press, Cocrystal Pharma Inc. From 12/22/21

Cocrystal Pharma (COCP) cited lab-based studies to indicate that the company’s oral and intranasal/pulmonary main protease inhibitors for COVID-19 showed antiviral effects against the Omicron variant of the virus. Cocrystal (NASDAQ:COCP) said that it would begin Phase 1 studies for COV...

Antiviral activity now confirmed against SARS-CoV-2 and all variants of concern including Omicron, Delta, Alpha, Beta and Gamma BOTHELL, Wash., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”...

Recorded December 8, 2021. Cocrystal Pharma Interim Co-CEOs Sam Lee, President and James Martin, CFO make a formal corporate presentation. Afterwards they are joined by Noble Capital Markets Senior Research Analyst Robert LeBoyer for a Q & A session featuring questions asked by the live au...

Check These Biotech Penny Stocks Out For Your Watchlist Right Now Finding the best biotech penny stocks to buy is all about understanding what catalysts are on the horizon. While most penny stocks are speculative, and therefore trade heavily on news and events, biotech stocks are es...

BOTHELL, Wash., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that President and interim CEO Sam Lee, Ph.D. and CFO and interim CEO James Martin will present a company overview in the Noble Ca...

Unveils designs for Phase 1 and 2 stud ies with intranasal/pulmonary and oral SARS-CoV-2 protease inhibitors ; trial initiations expected in 2022 BOTHELL, Wash., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“...

3Q21 Reported. Cocrystal reported a 3Q21 loss of $3.9 million or $(0.04) per share, compared with our expected loss of $3.1 million or $(0.03) per share. The company also confirmed the projected early 2022 start for its Phase 1 Influenza trial, and updated progress on the intranasal and orally...

Submitted pre-IND briefing package to the FDA for intranasal/pulmonary CDI-45205 for the treatment of COVID-19 and sets goal of initiating IND-enabling study and Phase 1 in 2022 Advance oral COVID-19 program with goal of initiating IND-enabling study and Phase 1 in 2022 Receiv...

BOTHELL, Wash., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral activity against human common coronaviruses,...

Cocrystal Pharma (NASDAQ:COCP) has added ~5.5% in the pre-market after the company disclosed the submission of a pre-Investigational New Drug (IND) briefing package to the FDA seeking to advance its experimental protease inhibitor CDI-45205 for the treatment of COVID-19. “We look ...